A systematic review and meta-analysis to determine whether or not taking antioxidant vitamin or mineral supplements, or both, prevent the development of AMD has found… Read More »Systematic review of antioxidant vitamin and mineral use in preventing AMD suggests no benefit when analysed in >76,000 people
Research, reported in EURETINA’s professional journal, Ophthalmologica, has shown that a treat-and-extend (“TAE”) regimen using aflibercept for typical AMD appears effective for improving AMD and… Read More »Research published in Ophthalmologica shows aflibercept “treat and extend” (TAE) protocol is efficacious in typical AMD patients.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the September 16th, 2017 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »September 16th, 2017: “EURETINA-Brief”© Issue No. 161
Applied Genetic Technologies Corp. (NASDAQ: AGTC), a gene therapy company based in Gainesville, Florida, has announced the submission of an Investigational New Drug (IND) application… Read More »AGTC Inc. in Florida files an investigational new drug application for X-linked retinitis pigmentosa
The results of long-term use of aflibercept in patients with macular edema has inidcated that the need for retreatment appears to be substantially reduced in… Read More »Long-term outcomes with aflibercept in diabetic macular edema (DME) – 5 year outcomes reported through extension of previous study
A Nature editorial has called for increased support from research scientists into translational medicine, specifically in regards to cutting edge and novel technologies now seeking… Read More »Expert research scientists in demand to support evaluation of new drug approvals for novel technologies, including retinal stem cell and gene therapies
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the September 1st, 2017 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »September 1st, 2017: “EURETINA-Brief”© Issue No. 160
GenSight Biologics Inc., (EURONEXT: SIGHT), Paris, France, have announced that their experimental GS010 treatment for LHON has completed enrollment in the company’s Phase III clinical… Read More »GenSight Biologics Inc. reports completion of Phase III enrolment for a gene therapy treatment for Leber’s Hereditary Optic Neuropathy (LHON)
GenSight Biologics Inc., (EURONEXT: SIGHT), Paris, France, have announced that their experimental GS010 treatment for LHON has completed enrollment in the company’s Phase III clinical… Read More »GenSight Biologics Inc. reports completion of Phase III enrolment for a gene therapy treatment for Leber’s Hereditary Optic Neuropathy (LHON)
The Clinical Research Institute (CRI) of the Foundation Fighting Blindness (FFB) has announced the enrollment of the first patient in a 4-year study to delineate… Read More »International clinical study, supported by Foundation Fighting Blindness, aims to establish the natural history of Usher syndrome type 2A